医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bioject Enters into Three Distribution Agreements

2013年03月21日 PM10:25
このエントリーをはてなブックマークに追加


 

TIGARD, Ore.

Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today announced that it has entered into three international distribution agreements, two in the Pacific Rim region and one in the Middle East. The agreements call for the sale of the Biojector®2000 gas-powered device, the Bioject® ZetaJet™ spring-powered device and accessories through qualified medical device groups located in Australia, the Republic of the Philippines, and North Africa. The agreements provide for distribution in multiple territories throughout the regions.

“We are pleased to have entered into these agreements, as it expands the use of our needle-free devices throughout the world,” said Mr. Mark Logomasini, Bioject’s President and CEO. “In partnership with our distributors, we are looking forward to developing relationships with new users of Bioject’s needle-free technology.”

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

Readers and potential investors are cautioned that an investment in the Company’s securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that these distribution agreements will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the business.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.

For more information about Bioject, visit www.bioject.com.

CONTACT

Bioject Medical Technologies Inc.
Mark Logomasini, 503-692-8001
ext. 4121
President and CEO
or
Christine Farrell,
503-692-8001 ext. 4132
Vice President of Finance

同じカテゴリーの記事 

  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表